The Latest Cardiac and Vascular News
SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) — REVA Medical Inc.(ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom bioresorbable scaffold (“BRS”) in Italy. The procedure was conducted by Dr. Bernardo Cortese at the Fatebenefratelli Hospital in Milan. “Fantom […]
MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the […]
WALTHAM, Mass.–(BUSINESS WIRE)– Corindus Vascular Robotics (NYSE American: CVRS), a leading developer of precision vascular robotics, announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions. The course series entitled “Complex Radial Interventions on Robotic and Manual Platforms” is designed to […]
ST. LOUIS PARK, Minn., Jan. 22, 2018 (GLOBE NEWSWIRE) — NeoChord, a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced a research collaboration with the Skirball Center for Innovation (SCI) at the Cardiovascular Research Foundation (CRF)to accelerate development of the company’s transcatheter […]
VANCOUVER, Jan. 23, 2018 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that the Chinese Center for Drug Evaluation (CDE) has approved an expansion of the indications for Aggrastat (tirofiban hydrochloride) to now, in addition to acute coronary syndromes […]
VANCOUVER, Jan. 22, 2018 /PRNewswire/ – Neovasc (“Neovasc” or the “Company“) (Nasdaq, TSX: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the “Board”) has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)– SurModics (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Telemark™ .014” coronary and peripheral support microcatheter. The Company is making this product available for U.S. distribution in the […]
DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International, Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the FDA approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common […]
by Ken Dropiewski, Prime-Core Executive Search (ken@prime-core.com) A new study published in the Journal of the American Heart Association shows that AMIs following a percutaneous coronary intervention (PCI) is twice as likely to originate from untreated lesions versus previous stented lesions. Interesting since this information seems to differ from previous studies such as PROSPECT […]
ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced two new partnerships broadening the company’s product portfolio. CSI is now the exclusive U.S. distributor of OrbusNeich balloon products. Additionally, the […]
